137 related articles for article (PubMed ID: 9934543)
1. Clinical and pharmacological evaluation of a modified cefotaxime bid regimen versus traditional tid in pediatric lower respiratory tract infections.
Boccazzi A; Tonelli P; Bellosta C; Careddu P
Diagn Microbiol Infect Dis; 1998 Dec; 32(4):265-72. PubMed ID: 9934543
[TBL] [Abstract][Full Text] [Related]
2. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
Brogden RN; Spencer CM
Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of the efficacy of cefotaxime sodium dosed twice daily. The Swedish experience.
Bergquist SO; Eriksson I; Eriksson S; Lönnbro N; Runehagen A; Styrud J; Ahlquist G
Diagn Microbiol Infect Dis; 1995; 22(1-2):163-6. PubMed ID: 7587033
[TBL] [Abstract][Full Text] [Related]
4. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
Plosker GL; Foster RH; Benfield P
Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
[TBL] [Abstract][Full Text] [Related]
5. Cefepime versus cefotaxime in the treatment of lower respiratory tract infections.
Barckow D; Schwigon CD
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():187-93. PubMed ID: 8150762
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options for cefotaxime in the management of bacterial infections.
Raddatz JK; Ostergaard BE; Rotschafer JC
Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of twice-daily cefotaxime in the treatment of hospitalized patients with severe infections.
Keller C
Diagn Microbiol Infect Dis; 1995; 22(1-2):159-61. PubMed ID: 7587032
[TBL] [Abstract][Full Text] [Related]
8. Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study.
Dulaney Lopez AM; Rodriguez JC; Lopez-Samblas AM; Estes KS
Int J Clin Pharmacol Ther; 1999 Jun; 37(6):269-74. PubMed ID: 10395117
[TBL] [Abstract][Full Text] [Related]
9. Review and reassessment of dosing schedules for cefotaxime in selected medical indications.
Young LS
Diagn Microbiol Infect Dis; 1995; 22(1-2):147-54. PubMed ID: 7587030
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.
Béranger A; Oualha M; Urien S; Genuini M; Renolleau S; Aboura R; Hirt D; Heilbronner C; Toubiana J; Tréluyer JM; Benaboud S
Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166
[TBL] [Abstract][Full Text] [Related]
11. Role of long-acting cephalosporins in the treatment of lower respiratory tract infections.
Lode H; Eller J; Raffenberg M; Mauch H
Clin Microbiol Infect; 2000; 6 Suppl 3():87-9. PubMed ID: 11449664
[No Abstract] [Full Text] [Related]
12. The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations.
Wilson WR; Bouza E; Lode H; Mouton Y
J Chemother; 1997 May; 9 Suppl 2():5-18. PubMed ID: 9248972
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of cefixime in treatment of respiratory tract infections in Germany.
Hausen T; Weidlich G; Schmitt J
Infection; 1995; 23 Suppl 2():S65-9. PubMed ID: 8537134
[TBL] [Abstract][Full Text] [Related]
14. Study of cefotaxime twice daily for the therapy of postoperative pneumonia. The German Cefotaxime Study Group.
Bruch HP; Kujath P
Diagn Microbiol Infect Dis; 1995; 22(1-2):203-7. PubMed ID: 7587041
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections.
Pareek A; Kulkarni M; Daga S; Deshpande A; Chandurkar N
Expert Opin Pharmacother; 2008 Nov; 9(16):2751-7. PubMed ID: 18937610
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ceftizoxime administered twice daily in hospitalized patients with respiratory tract infections.
Lentnek A; Wikler M; McDevitt J; Sohn C
Clin Ther; 1984; 7(1):33-9. PubMed ID: 6097357
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of cefixime.
Tally FP; Desjardins RE; McCarthy EF; Cartwright K
Pediatr Infect Dis J; 1987 Oct; 6(10):976-80. PubMed ID: 3320926
[TBL] [Abstract][Full Text] [Related]
18. Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. The Italian Multicentre Community-Acquired Pneumonia Group.
De Palma M; Rocchi D; Canepa G; Peri A; Cantone V
Clin Ther; 1995; 17(3):413-24. PubMed ID: 7585845
[TBL] [Abstract][Full Text] [Related]
19. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics.
Nix DE; Schentag JJ
Diagn Microbiol Infect Dis; 1995; 22(1-2):71-6. PubMed ID: 7587053
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cefotaxime and desacetylcefotaxime in the young.
Kearns GL; Young RA
Diagn Microbiol Infect Dis; 1995; 22(1-2):97-104. PubMed ID: 7587057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
